Feng Yifan, Wu Chenyang, Chen Huan, Zheng Tingting, Ye Hanyi, Wang Jinrui, Zhang Yinghua, Gao Jia, Li Ying, Dong Zhengqi
Drug Delivery Research Center, Institute of Medicinal Plant Development, Chines Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Jilin Provincial Academy of Chinese Medicine, Changchun, China.
Front Pharmacol. 2023 Jun 20;14:1184183. doi: 10.3389/fphar.2023.1184183. eCollection 2023.
Inflammatory bowel disease (IBD) affects about 7 million people globally, which is a chronic inflammatory condition of the gastrointestinal tract caused by gut microbiota alterations, immune dysregulation, genetic and environmental factors. Nanoparticles (NPs) deliver an active natural compound to a site harbored by disordered microbiota, they are used to interact, target and act intentionally on microbiota. Although there is accumulating evidence indicating that berberine and polysaccharide play an important role in IBD via regulating microbiota, there is limited research that presents a complete picture of exactly how their carrier-free co-assembled nanodrug affects IBD. The study establishes the carrier-free NPs formed by berberine and rhubarb polysaccharide based on the combination theory of and , and characterizes the NPs. The IBD treatment efficacy of NPs are evaluated via IBD efficacy index, and explore the mechanism of NPs via 16S rRNA test and immunohistochemistry including occludin and zonula occludens-1. The results showed that DHP and BBR were co-assembled to nanoparticles, and the BD can effectively relieve the symptoms of UC mouse induced by DSS via regulating gut microbiota and repair the gut barrier integrity, because BD have a longer retention on the colon tissue and react with the microbiota and mucus thoroughly. Interestingly, BD can enrich more probiotic than free BBR and DHP. This design provides a better strategy and encourages future studies on IBD treatment via regulating gut microbiota and the design of novel plant polysaccharide based carrier-free co-assembly therapies.
炎症性肠病（IBD）在全球约影响700万人，它是一种由肠道微生物群改变、免疫失调、遗传和环境因素引起的胃肠道慢性炎症性疾病。纳米颗粒（NPs）将活性天然化合物递送至微生物群紊乱的部位，用于与微生物群进行相互作用、靶向并有意作用于微生物群。尽管越来越多的证据表明黄连素和多糖通过调节微生物群在IBD中发挥重要作用，但关于其无载体共组装纳米药物究竟如何影响IBD的全面研究却很有限。该研究基于[具体理论名称]的组合理论，建立了由黄连素和大黄多糖形成的无载体纳米颗粒，并对其进行了表征。通过IBD疗效指数评估纳米颗粒的IBD治疗效果，并通过16S rRNA检测以及包括闭合蛋白和紧密连接蛋白-1在内的免疫组织化学方法探究纳米颗粒的作用机制。结果表明，大黄素和黄连素共组装成纳米颗粒，且BD可通过调节肠道微生物群并修复肠道屏障完整性有效缓解由葡聚糖硫酸钠（DSS）诱导的UC小鼠的症状，因为BD在结肠组织上具有更长的滞留时间，并能与微生物群和黏液充分反应。有趣的是，BD比游离的黄连素和大黄素能富集更多的益生菌。该设计提供了一种更好的策略，并鼓励未来开展关于通过调节肠道微生物群治疗IBD以及基于新型植物多糖的无载体共组装疗法设计的研究。
